Physician profile
David A Wadowski
NPI 1952314122
$1,746.96
in general payments reported to CMS, 2019-2025
19 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.86 · 2020: $45.59 · 2021: $184 · 2022: $314 · 2023: $72.07 · 2024: $765 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641 · Travel and Lodging: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.82 |
| Travel and Lodging | $494.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $794.31 | 2022-2025 | Hydrus Microstent, Argos, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $162.89 | 2019-2021 | |
| Abbvie INC. | $120.47 | 2022-2023 | Lumigan, Vuity, Alphagan P |
| Glaukos Corporation | $110.31 | 2022-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $102.36 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $65.78 | 2022 | |
| Sun Pharmaceutical Industries INC. | $52.63 | 2021-2024 | |
| Apellis Pharmaceuticals, INC. | $50.64 | 2025 | Syfovre |
| Dompe US, INC. | $50.55 | 2021-2024 | Oxervate |
| Allergan, INC. | $48.50 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $33.92 | 2024 | Xdemvy |
| Beaver-Visitec International, INC. | $24.51 | 2021 | |
| Shire North American Group INC | $22.14 | 2019 | |
| Amgen INC. | $22.14 | 2025 | Tepezza |
| Rayner Intraocular Lenses Limited | $22.08 | 2024 | Omidria, Rayone Aspheric, Rayone Emv |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $19.25 | 2025 | Iheezo |
| Ocular Therapeutix, INC. | $16.82 | 2025 | Dextenza |
| Eyevance Pharmaceuticals LLC | $16.05 | 2022 | |
| Aerie Pharmaceuticals, INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wadowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.